Myrtelle

New York, NY · Founded 2020 · Privately Held (backing)

Operator of a gene therapy company intended to offer innovative clinical trials for the treatment of the rare monogenic disorder. Myrtelle is based in New York, NY and was founded in 2020. Its last reported valuation was $134 million in Dec 2022. It has raised $82.6 million across 4 recorded rounds; the latest was a $30.5 million early-stage round in Dec 2025.

Last reported valuation
$134.0M
Oct 2026
Priced at
—
Total raised
$82.6M
Last round
Early Stage VC
Dec 2025

Who backs Myrtelle?

3 investors
InvestorType
Panacea VentureVenture capital
F1 BioVentures—
Panacea Capital (California)—
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Myrtelle investors

3 investors are on record for Myrtelle, including Panacea Venture, F1 BioVentures and Panacea Capital (California). The early-stage round in Dec 2025 drew 21 investors.

Free account
More of Myrtelle with a free account
  • ·Watch Myrtelle: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 3 firms already write checks for companies like Myrtelle. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View